

**Press release**

**22 June, 2024**

## **Curasight to present at HC Andersen Capital**

**Copenhagen, Denmark, 22 June 2024 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the new capitalization and funding of the company at HC Andersen Capital 25 June 2024.**

The transaction announced on 14 June 2024 provides potential new funding up to DKK 120 million. Full financing will extend the cash runway well into the second half of 2025. The funding ensures strategic flexibility and supports the continued pipeline development. In terms of the pipeline, Curasight has just enrolled the first patient in its phase 2 clinical trial with uTRACE® in prostate cancer under the Curium Pharma license agreement.

At the upcoming webcast at HC Andersen Capital management will create an overview of the funding structure. Further, Curasight will update shareholders on strategic execution over the next 12 to 18 months.

**The HC Andersen Capital presentation will be webcasted live 10:15 - 10:45 (CET), Tuesday 25 June 2024.**

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight's website, after the presentation is completed.

For more information – please [click here](#)

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO  
Phone: +45 22 83 01 60  
E-mail: [uk@curasight.com](mailto:uk@curasight.com)  
[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE) and Radioligand Therapy (uTREAT) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.